Herbert Pang

7.5k total citations · 2 hit papers
145 papers, 5.2k citations indexed

About

Herbert Pang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Herbert Pang has authored 145 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 45 papers in Oncology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Herbert Pang's work include Gene expression and cancer classification (18 papers), Statistical Methods in Clinical Trials (17 papers) and Lung Cancer Treatments and Mutations (15 papers). Herbert Pang is often cited by papers focused on Gene expression and cancer classification (18 papers), Statistical Methods in Clinical Trials (17 papers) and Lung Cancer Treatments and Mutations (15 papers). Herbert Pang collaborates with scholars based in United States, Hong Kong and China. Herbert Pang's co-authors include Anna Mae Diehl, Manal F. Abdelmalek, Ayako Suzuki, Hongyu Zhao, Everett E. Vokes, Cynthia D. Guy, Elizabeth Smith, Constance Cirrincione, Electra D. Paskett and Stewart B. Fleishman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Herbert Pang

139 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy

2013 718 citations Elizabeth Smith, Herbert Pang et al. JAMA profile →
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies

2017 266 citations Xiaofei Wang, Herbert Pang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Herbert Pang United States	37	1.5k	1.4k	1.2k	917	527	145	5.2k
Borko Jovanovic United States	38	1.4k 0.9×	1.2k 0.9×	793 0.6×	1.1k 1.2×	312 0.6×	118	6.0k
Mark H. Wener United States	50	1.2k 0.8×	1.6k 1.2×	1.4k 1.1×	920 1.0×	764 1.4×	153	9.0k
Karen H. Costenbader United States	59	605 0.4×	1.3k 0.9×	1.1k 0.9×	768 0.8×	941 1.8×	290	12.3k
Jean‐Pierre Daurès France	43	1.1k 0.7×	913 0.7×	534 0.4×	1.2k 1.3×	467 0.9×	168	6.8k
Takuhiro Yamaguchi Japan	42	1.4k 0.9×	781 0.6×	544 0.4×	1.2k 1.3×	200 0.4×	334	7.6k
Aesun Shin South Korea	48	2.2k 1.4×	846 0.6×	1.2k 1.0×	1.1k 1.2×	255 0.5×	270	6.8k
Lin Zhang China	39	1.9k 1.2×	1000 0.7×	1.2k 1.0×	842 0.9×	134 0.3×	306	8.3k
Elizabeth W. Karlson United States	55	495 0.3×	1.5k 1.1×	1.1k 0.9×	687 0.7×	487 0.9×	174	9.4k
Jacques Bénichou France	52	1.6k 1.1×	1.2k 0.9×	849 0.7×	2.2k 2.5×	144 0.3×	231	10.2k
Susan Bayliss United Kingdom	43	1.1k 0.7×	1.7k 1.2×	289 0.2×	554 0.6×	429 0.8×	122	5.4k

Countries citing papers authored by Herbert Pang

Since Specialization

Citations

This map shows the geographic impact of Herbert Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Pang more than expected).

Fields of papers citing papers by Herbert Pang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Pang. The network helps show where Herbert Pang may publish in the future.

Co-authorship network of co-authors of Herbert Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Pang. A scholar is included among the top collaborators of Herbert Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Pang. Herbert Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Di, Junrui, Nadia Daizadeh, Ying Lü, et al.. (2025). Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective. Clinical and Translational Science. 18(2). e70117–e70117. 10 indexed citations

Tao, Jun, Jianchao Quan, Aya El Helali, Wwt Lam, & Herbert Pang. (2023). Global trends indicate increasing consumption of dietary sodium and fiber in middle-income countries: A study of 30-year global macrotrends. Nutrition Research. 118. 63–69. 5 indexed citations

Pang, Herbert, et al.. (2023). Covariate handling approaches in combination with dynamic borrowing for hybrid control studies. Pharmaceutical Statistics. 22(4). 619–632. 8 indexed citations

Zhu, Shuying, et al.. (2023). CPAE: Contrastive predictive autoencoder for unsupervised pre-training in health status prediction. Computer Methods and Programs in Biomedicine. 234. 107484–107484. 4 indexed citations

Zhang, Siqi, Jianrong Zhang, Sida Liu, et al.. (2023). Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019). JCO Oncology Practice. 19(11). 1058–1068. 2 indexed citations

Pang, Herbert, Jiawen Zhu, Hans‐Joachim Helms, et al.. (2023). Evaluating hybrid controls methodology in early‐phase oncology trials: A simulation study based on the MORPHEUS‐UC trial. Pharmaceutical Statistics. 23(1). 31–45. 4 indexed citations

Gill, Harinder, Garret M. K. Leung, Rita Yim, et al.. (2020). Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting. Hematology. 25(1). 247–257. 11 indexed citations

Mao, Xiaowen, Sze Keong Tey, Cherlie Lot Sum Yeung, et al.. (2020). Nidogen 1‐Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. Advanced Science. 7(21). 2002157–2002157. 72 indexed citations

Zhao, Hongyu, et al.. (2020). An enhanced machine learning tool for cis‐eQTL mapping with regularization and confounder adjustments. Genetic Epidemiology. 44(8). 798–810. 1 indexed citations

10.

Du, Richard, Victor Lee, Hui Yuan, et al.. (2019). Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. Radiology Artificial Intelligence. 1(4). e180075–e180075. 46 indexed citations

11.

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2018). Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. Molecular Cancer Therapeutics. 17(10). 2248–2256. 15 indexed citations

12.

Poulos, Rebecca C., et al.. (2018). Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. PLoS Genetics. 14(11). e1007779–e1007779. 35 indexed citations

13.

Schild, Steven E., Thomas E. Stinchcombe, Everett E. Vokes, et al.. (2018). Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(2). 298–303. 14 indexed citations

14.

Ni, Michael Y., Herbert Pang, Brandford H. Y. Chan, et al.. (2016). Direct Participation in and Indirect Exposure to the Occupy Central Movement and Depressive Symptoms: A Longitudinal Study of Hong Kong Adults. American Journal of Epidemiology. 184(9). 636–643. 22 indexed citations

15.

Liu, Yingmiao, Mark D. Starr, John C. Brady, et al.. (2015). Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics. 14(4). 1048–1056. 18 indexed citations

16.

Jia, Jingquan, Andrew Dellinger, Eric S. Weiss, et al.. (2015). Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clinical Cancer Research. 21(15). 3442–3452. 4 indexed citations

17.

Smith, Elizabeth, Herbert Pang, Constance Cirrincione, et al.. (2013). Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. JAMA. 309(13). 1359–1359. 718 indexed citations breakdown →

18.

Salama, Joseph K., Lydia Hodgson, Herbert Pang, et al.. (2013). A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904. Journal of Thoracic Oncology. 8(8). 1043–1049. 28 indexed citations

19.

Wong, Nan Soon, Nishan H. Fernando, Johanna C. Bendell, et al.. (2011). A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 10(3). 210–216. 9 indexed citations

20.

Dubey, Sarita, Pasi A. Jänne, Lee M. Krug, et al.. (2010). A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology. 5(10). 1655–1661. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact